Conservatives pledge to invest in preventing and curing disease in election manifesto
November 26, 2019Manufacturing and Production Boris Johnson, Conservative Party, Election 2019, Tories NHS, Tory Manifesto
Prime Minister Boris Johnson launched the Conservative Party’s manifesto on Sunday, promising to invest more into research to prevent and …
The coming age of biosimilars
November 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biosimilars, feature, pharma
With more and more biosimilars securing approval and the sheer potential value they have to offer for healthcare systems around …
Sanofi’s head of strategy and business development to retire amid company review
November 25, 2019Sales and Marketing Bristol Meyers, Gilead, Sanofi, Shell
One of Sanofi’s most senior strategy bosses is set to retire at the end of the month. Muzammil Mansuri, Executive …
FDA approves AstraZeneca’s Calquence in chronic lymphoma
November 25, 2019Sales and Marketing Astrazenaca, Calquence, FDA, Health Canada, leukaemia, oncology
The FDA has approved AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) in the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic …
FDA fast-tracks psilocybin treatment for major depressive disorder
November 25, 2019Sales and Marketing Controlled Substance Act, FDA, breakthrough therapy, major depressive disorder, psilocybin
The FDA has granted a Breakthrough Therapy designation to the Usona Institute for its trial use of psilocybin in the …
Novartis acquires The Medicines Company in a deal worth $9.7 billion
November 25, 2019Sales and Marketing Novartis, The Medicines Company, pharma
Novartis agreed a $9.7 billion deal to acquire the US-based The Medicines Company, it announced Sunday. The transaction was unanimously …
Roche’s Tecentriq combo outclasses Nexavar in unresectable hepatocellular carcinoma
November 25, 2019Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq
Roche has revealed new Phase 3 data for its immunotherapy drug Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …
Scotland leading the UK in life science start-up growth, report reveals
November 20, 2019Research and Development, Sales and Marketing BioCity, UK, biotech, pharma
A new report published by the life science incubator and business collective BioCity has painted a promising picture of UK …
Lilly to boost Indianapolis manufacturing site with $400m injection, 100 jobs to be created
November 20, 2019Manufacturing and Production, Research and Development Eli Lilly, US, pharma
Eli Lilly is poised to boost its manufacturing capacity with the investment of $400 million at its Lilly Technology Center …
Europe approves Keytruda for first-line head and neck squamous cell carcinoma, as a monotherapy or combo
November 20, 2019Research and Development, Sales and Marketing Cancer, keytruda, pharma
MSD’s top-selling immunotherapy Keytruda (pembrolizumab) has secured another approval from the European Commission, this time in the first-line treatment of …
Allergan’s acute migraine therapy ubrogepant shows strength at Phase 3
November 20, 2019Research and Development Allergan, pharma, ubrogepant
Allergan has revealed positive Phase 3 data on its oral calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant, illustrating the therapy’s …
European Commission approves Genmab’s Darzalex combo in newly diagnosed multiple myeloma
November 20, 2019Research and Development, Sales and Marketing Europe, Genmab, darzalex, pharma
Genmab’s Darzalex (daratumumab) has secured approval from the European Commission and is now authorised in Europe for the treatment of …
Keytruda overtakes Opdivo to lead sales in global immune checkpoint inhibitor market, report reveals
November 19, 2019Manufacturing and Production, Sales and Marketing Bristol-Myers Squibb, MSD, keytruda, opdivo, pharma
MSD’s Keytruda (pembrolizumab) overtook Bristol-Myers Squibb’s (BMS) blockbuster drug Opdivo (nivolumab) in total sales in the third quarter of 2019 …
Amgen poised to cut 172 positions across US, including California HQ
November 19, 2019Manufacturing and Production Amgen, US, pharma
As revealed in correspondence with the California Employment Development Department, Amgen plans to axe 172 staff positions across the US, …
Bayer and MSD’s chronic heart failure drug meets main goal at Phase 3
November 19, 2019Manufacturing and Production, Research and Development Bayer, MSD, pharma, vericiguat
MSD and Bayer have made it known that their jointly-developed soluble guanylate cyclase (sGC) stimulator vericiguat met its primary endpoint …
Data revealed on novel CRISPR/Cas9 gene-editing therapy for first two severe haemoglobinopathy patients
November 19, 2019Manufacturing and Production, Research and Development Vertex, crispr, pharma
Vertex and CRISPR Therapeutics have unveiled the first interim Phase 1/2 data demonstrating the safety and efficacy of the investigational …
Alkermes snaps up Rodin Therapeutics for a potential $950 million
November 19, 2019Manufacturing and Production, Sales and Marketing Alkermes, Rodin Therapeutics, pharma
Dublin’s Alkermes is set to acquire US firm Rodin Therapeutics in a deal worth a potential $950 million, it has …
Bringing the clinical trial home
November 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trials, feature, research
Clinical trials are the backbone of healthcare and drug research, but many key patient populations have in the past been …
Pfizer’s Humira biosimilar secures FDA approval, due to launch in 2023
November 18, 2019Sales and Marketing Abrilada, FDA, Humira, Pfizer, biosimilar, pharma
Pfizer has confirmed the FDA approval of Abrilada (adalimumab-afzb), its biosimilar version of AbbVie’s Humira, the world’s best-selling drug, …
EMA advisory panel recommends Mayzent for secondary progressive multiple sclerosis
November 18, 2019Sales and Marketing Europe, Mayzent, Novartis, multiple sclerosis, pharma
Novartis has revealed that Mayzent (siponimod) has been recommended by the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
